Grail's Multi-Cancer Blood Test Shows Mixed Results in Early Detection Trials
Grail, a Silicon Valley healthcare company, has presented its largest study to date on the Galleri blood test at the American Society of Clinical Oncology meeting in Chicago. The test, priced at $950, aims to detect over 50 types of cancer by identifying cancer DNA in the bloodstream. The study involved more than 140,000 older individuals in the UK, assessing the test's ability to detect cancer before it reaches advanced stages. While the test increased cancer detection rates when combined with standard screenings, it was less effective at identifying early-stage cancers, which are generally easier to treat. The test is not yet FDA-approved but is available in the U.S. with a prescription. 
